REDWOOD CITY, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced that results regarding the company's Oncotype DX(TM) breast cancer test, which quantifies the likelihood of recurrence and predicts the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients, will be presented at the 29th Annual San Antonio Breast Cancer Symposium, taking place December 14-17, 2006. Following are details for each embargoed session (all times are Central Standard Time):
Friday, December 15, 2006, 5:00 p.m. to 7:00 p.m. -- Abstract #3116 Poster presentation: "A comparison of estrogen receptor (ER) measurement by three methods in node negative, estrogen receptor (ER) positive breast cancer: ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PCR." Presenter: Chungyeul Kim, M.D., National Surgical Adjuvant Project (NSABP) -- a National Cancer Institute-funded cooperative study group Sunday, December 17, 7:00 a.m. - 9:00 a.m. -- Abstract #6039 Poster presentation: "The impact on the Recurrence Score due to patient variation in the quantitative expression of individual genes or gene groups." Presenter: Drew Watson, Ph.D. -- Abstract #6118 Poster presentation: "Subtypes of breast cancer defined by standardized quantitative RT-PCR analysis of 10,618 tumors." Presenter: Steven Shak, M.D. -- Abstract #6111 Poster presentation: "Relationship between proliferation genes and expression of hormone and growth factor receptors: quantitative RT-PCR in 10,618 breast cancers." Presenter: Steven Shak, M.D. Sunday, December 17 at 10:30 a.m. -- Abstract #45 Oral presentation: Quantitative RT-PCR analysis of ER and PR by Oncotype DX indicates distinct and different associations with prognosis and prediction of tamoxifen benefit Presenter: Frederick L. Baehner, M.D. About Oncotype DX
Oncotype DX represents the first diagnostic multi-gene expression test service commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of patient survival within 10 years of diagnosis and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 2,600 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. For more information about Oncotype DX, please visit http://www.oncotypedx.com .
About Genomic Health
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com .
Genomic Health, Inc.CONTACT: Media, Emily Faucette, +1-415-946-1066, ormedia@genomichealth.com, for Genomic Health, Inc.; or Investors, Brad Coleof Genomic Health, Inc., +1-650-569-2281, or investors@genomichealth.com
